Stock Hideout

Thursday, September 25 2008 9:00 AM, EST

Albumax Has Been Approved by Medicaid in California & Pennsylvania

Market Wire "US Press Releases "

HUNTINGTON STATION, NY -- (MARKET WIRE) -- 09/25/08 --
Medivisor, Inc. (PINKSHEETS: MVSR)
announced today that Albumax has been approved by the California and the
Pennsylvania State Medicaid Offices. Albumax has previously received
approval from the New York State Medicaid Office. Albumax has been
approved under code B4155 as an enteral product. This approval allows for
Medicaid reimbursement of costs for eligible patients using Albumax.
Medicaid is the largest source of funding for medical and health-related
services for people with limited income. It is an entitlement program that
is jointly funded by the states and federal government, and is managed by
the states. Among the groups of people served by Medicaid are eligible
low-income parents, children, seniors, and people with disabilities.

"These additional Medicaid approvals are extremely important for the
national rollout of Albumax," said Mr. Dino Luzzi, CEO of Medivisor, Inc.
"Medicaid acceptance for Albumax increases the willingness of providers and
patients to use Albumax to increase blood albumin levels in kidney disorder
patients," continued Mr. Luzzi. Patients and those in the Medical
Profession can now go to Albumax supplies dialysis patients only high quality protein along with two essential amino acids in a powder form that may be mixed with or sprinkled on other foods. This avoids raising the fluid intake of the patient with use of the supplement and to order or inquire about the
product.

About Medivisor, Inc.:

Medivisor, Inc. is a developer of next-generation focus driven marketing
tools, dedicated to providing technologies that offer innovative and
competitive advantages to the bioscience and pharmaceutical markets. From
pre-product development through product launch and commercialization,
Medivisor offers worldwide experience in delivering effective and
successful integrated marketing and creative communications campaigns for
the benefit of its clients.

Safe Harbor

This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995 (the "Act").
Additionally, words such as "seek," "intend," "believe," "plan,"
"estimate," "expect," "anticipate" and other similar expressions are
forward-looking statements within the meaning of the Act. Some or all of
the events or results anticipated by these forward-looking statements may
not occur. Further information on Medivisor risk factors is contained in
its filings with the Securities and Exchange Commission. Medivisor does not
undertake any duty nor does it intend to update the results of these
forward-looking statements.

Contact:
Dino Luzzi
CEO
Medivisor, Inc.
Tel: 631.549.7100
Email Contact

There are many latent indications of an imminent rally in shares of MVSR. For starters, there have been many upside volume spikes acccompanied by very low volume bouts of profit-taking. The stochastics is in a strong uptrend ---but is far from overbought levels. The short MACD average has just crossed back above the longer average. And most importantly (in my opinion) is the fact that while the sstock has been making lower-lows, the MACD has been making considerably higher-lows. This bullish divergence suggests that a strong upside rally is in the cards over the next several days. Could be a good time to take a position in this company now.

Thanks pro_trader Ive got it on radar.

__________________
All my posts are purely my opinion. Please use your own buy and sell signals and never invest in a stock you can not afford to lose money on. For a complete disclaimer click here

Medivisor Inc.; Reiterated 'Speculative Buy' Rating, Target Price $0.87 by Beacon Equity Research
DALLAS, Oct 02, 2008 (BUSINESS WIRE) --
Medivisor Inc. (Pink Sheets: MVSR) has received a reiterated Speculative Buy rating with a price target of $0.87 by Beacon Analyst, Victor Sula, Ph.D.
The full report is available at Medivisor, Inc / Adpages / Page data / Home - BEACON Equity Research.
Anyone interested in receiving alerts regarding MVSR research should e-mail members@beaconequity.com with "MVSR" in the subject line.
In the report, the analyst writes, "MVSR is a medical communications company dedicated to providing concise and timely medical information to healthcare industry professionals. MVSR has several exclusive deals with drug manufacturers to market their products for important shares of profits from drug sales. ... The Company is also preparing the launch into the billion dollar energy drink sector. MVSR intends to begin marketing its own targeted energy drink initially throughout the European continent."
Other companies involved in medical business services include: PDI Inc. (Nasdaq: PDII), inVentive Health Inc. (Nasdaq: VTIV), Omnicom Group Inc. (NYSE: OMC) and Publicis Groupe SA (PUBP.PA).
Beacon Equity Research Disclosure
The analysts contributing to this report certify that the views expressed herein accurately reflect the analysts' personal views as to the subject securities and issuers. BeaconEquity.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BeaconEquity.com is a wholly owned entity of BlueWave Advisors, LLC, which has been compensated forty three thousand five hundred dollars from Universal Management Services as a marketing budget to manage a comprehensive investor awareness program including the creation and distribution of this report as well as other investor relations efforts. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Please read our report and visit our Web site, BeaconEquity.com, for complete disclosures.

Nice day today congrats to all who got in.

Medivisor, Inc. (OTC: MVSR), developer of next-generation focus driven marketing tools, announced that it has expanded its previously announced Albumax marketing agreement. Medivisor has expanded its original agreement covering US distribution and Medivisor now has the exclusive right to distribute Albumax in Korea. Albumax, a whey protein isolate formula, makes it easy for Kidney disorder patients to reach their daily requirements of high quality protein in their diet. Medivisor anticipates consummating a distribution relationship in Korea shortly.
According to The Kidney Alliance, a UK organization and sponsor of World Kidney Day, worldwide, more than 500 million people are living with some form of kidney disease; approximately one out of every ten adults has some form of kidney damage. People with chronic kidney disease are 10 times more likely than healthy individuals to die of heart attacks and strokes. South Korea's population is 49,232,844; North Korea's population is 23,479,089.
"We have recently received several inquiries regarding distribution of a number of our products in Korea," stated Dino Luzzi, CEO of Medivisor, Inc. "Medivisor is committed to expanding our existing distribution capabilities in both the United States and Korea, and broadening our customer relationships. We intend to use Korea as a starting point to launch Albumax, and other products throughout the rest of the Far East."

Holding up well in a nasty tape!! Shares very cheap right now and look to move higher

Shares of MVSR are very oversold and are now on their second day of advance. Pinnacle Digest considers MVSR a "company of interest" today in their online financial magazine. While I would like to see the volume expanding, rather than contracting, I think this could be a very profitable trade. Beacon is also having an online forum with the CEO on Friday.That could be marketing moving as well.

Wednesday, October 15 2008*8:30 AM, EST

Medivisor, Inc. Signs Additional Agreement for Distribution of 'Maximum Energy Shot'; Terms Include $500,000 Minimum Orders for Renewable Contract

Market Wire ***"US Press Releases "

HUNTINGTON STATION, NY -- (MARKET WIRE) -- 10/15/08 -- Medivisor, Inc. (PINKSHEETS: MVSR), developer of next-generation focus driven marketing tools, announced today that it has entered into an agreement with Stack-It Distributors, Inc. for the distribution of its newly announced energy drink, Maximum Energy Shot. Medivisor has retained Stack-It Distributors, Inc. to distribute its energy drink, and Stack-It Distributors Inc. is to provide minimum orders of $500,000 for an annually renewable contract. The agreement with Stack-It Distributors is substantially similar to Medivisor's previously announced agreement with Market Quest USA .

"Industry dynamics are changing at a rapid pace and the opportunity to enter into the fastest growing segment of the beverage industry, energy drinks, along side of Medivisor, Inc. is a great opportunity," stated Stack-It President Robert Kaible. "We share common vision and values and expect the brand, Maximum Energy Shot, to be a sales success."

Stack-It Distributors, Inc. is a full-service distribution company committed to being the beverage distributor of choice in the Northeast, sustaining profitable growth for the brands it represents. Headquartered on Long Island, NY, Stack-It prides itself on providing remarkable service to its customers and providing a great culture for its teammates.

About Medivisor, Inc. :

Medivisor, Inc. is a developer of next-generation focus driven marketing tools, dedicated to providing technologies that offer innovative and competitive advantages to the bioscience and pharmaceutical markets. From pre-product development through product launch and commercialization, Medivisor offers worldwide experience in delivering effective and successful integrated marketing and creative communications campaigns for the benefit of its clients.

Safe Harbor

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Additionally, words such as "seek," "intend," "believe," "plan," "estimate," "expect," "anticipate" and other similar expressions are forward-looking statements within the meaning of the Act. Some or all of the events or results anticipated by these forward-looking statements may not occur. Further information on Medivisor risk factors is contained in its filings with the Securities and Exchange Commission . Medivisor does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Contact: Dino Luzzi CEO Medivisor, Inc. Tel: 631.549.7100 Email Contact